CD4 and neoplasm: TOCA 511 resulted in the promotion of T cell expansion (Th1, Th2 in CD4+, CD8+), mediated antitumor immune response, and concentrated the effect of drugs at the tumor site which increased direct tumor cell death, alterations in immune cell infiltration, and improved survival [174,175,176,177,178].